Barclays Maintains American Renal Associates to Overweight with Price Target $29.00

Brokerage firm Barclays Maintains its rating on American Renal Associates(NYSE:ARA). In a research note issued to the investors, the brokerage major Lowers the price-target to $29.00 per share. The shares have been rated Overweight. The rating by Barclays was issued on Aug 19, 2016.

American Renal Associates(ARA) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $185.57M. Analysts had an estimated revenue of $177.91M. Earnings per share were $0.26. Analysts had estimated an EPS of $0.22.

Several Insider Transactions has been reported to the SEC. On Apr 27, 2016, Syed T Kamal (PRESIDENT) purchased 500 shares at $22.00 per share price.Also, On Apr 27, 2016, Michael Ray Costa (VP, GC AND SECRETARY) purchased 370 shares at $22.00 per share price.On Apr 27, 2016, Joseph A Carlucci (CEO) purchased 500 shares at $22.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

American Renal Associates - Is it time to Sell?

Top Brokerage Firms are advising their investors on American Renal Associates. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.